NovaBridge Biosciences (NBP)

US — Healthcare Sector
Peers: GALT  DSGN  DMAC  AURA  RCKT  ANNX  DRTS  LBRX  ENGN  ALT 

Automate Your Wheel Strategy on NBP

With Tiblio's Option Bot, you can configure your own wheel strategy including NBP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NBP
  • Rev/Share 0.0
  • Book/Share 2.408
  • PB 12.5014
  • Debt/Equity 0.0177
  • CurrentRatio 22.8175
  • ROIC -0.1906

 

  • MktCap 3469927877.6468
  • FreeCF/Share 0.0
  • PFCF 0.0
  • PE -64.3716
  • Debt/Assets 0.0168
  • DivYield 0
  • ROE -0.1877

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About NovaBridge Biosciences (NBP)

  • IPO Date 2020-01-17
  • Website https://www.i-mabbiopharma.com
  • Industry Biotechnology
  • CEO Xi-Yong Fu
  • Employees 32
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.